NYSE:USNA - USANA Health Sciences Stock Price, Price Target & More

USANA Health Sciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "USNA."

USANA Health Sciences declared that its board has initiated a stock buyback program on Wednesday, July 26th 2017, which allows the company to buyback $64,600,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 46% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's management believes its stock is undervalued.

USANA Health Sciences, Inc. (NYSE:USNA) issued its quarterly earnings data on Tuesday, April, 24th. The company reported $1.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.05 by $0.14. The business had revenue of $292 million for the quarter, compared to analyst estimates of $268.93 million. USANA Health Sciences had a net margin of 6.47% and a return on equity of 27.92%. The business's revenue was up 14.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.91 EPS. View USANA Health Sciences' Earnings History.

USANA Health Sciences is scheduled to release their next quarterly earnings announcement on Monday, July, 23rd 2018. View Earnings Estimates for USANA Health Sciences.

USANA Health Sciences updated its FY18 earnings guidance on Tuesday, April, 24th. The company provided earnings per share guidance of $4.25-4.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.37. The company issued revenue guidance of $1.13-1.17 billion, compared to the consensus revenue estimate of $1.12 billion.

2 brokers have issued 1-year target prices for USANA Health Sciences' shares. Their predictions range from $95.00 to $95.00. On average, they anticipate USANA Health Sciences' share price to reach $95.00 in the next twelve months. View Analyst Ratings for USANA Health Sciences.

Some companies that are related to USANA Health Sciences include Stada Arzneimittel (STDAF), ChromaDex (CDXC), Foamix Pharmaceuticals (FOMX), MediWound (MDWD), Natural Alternatives International (NAII), Mannatech (MTEX), Pharmacyte Biotech (PMCB), China Jo-Jo Drugstores (CJJD), GLG Life Tech (GLGLF), Cyanotech (CYAN), ImmuDyne (IMMD), FitLife Brands (FTLF), Nutra Pharma (NPHC), Tauriga Sciences (TAUG) and True Drinks (TRUU).

News articles about USNA stock have been trending somewhat positive this week, according to Accern Sentiment. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. USANA Health Sciences earned a daily sentiment score of 0.05 on Accern's scale. They also assigned headlines about the company an impact score of 45.13 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.

USANA Health Sciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.45%), Dimensional Fund Advisors LP (3.23%), Schroder Investment Management Group (1.38%), Matarin Capital Management LLC (0.65%), Hood River Capital Management LLC (0.63%) and Russell Investments Group Ltd. (0.57%). Company insiders that own USANA Health Sciences stock include Daniel A Macuga, Dave Wentz, David Mulham Mulham, Deborah Woo, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, James Bramble, Jim Brown, Kevin Guest, Myron W Wentz, Paul A Jones, Robert Auciaux and Walter Noot. View Institutional Ownership Trends for USANA Health Sciences.

USNA stock was sold by a variety of institutional investors in the last quarter, including Schroder Investment Management Group, BNP Paribas Arbitrage SA, UBS Group AG, Hays Advisory LLC, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp, Guggenheim Capital LLC, Camarda Financial Advisors LLC and New York State Common Retirement Fund. Company insiders that have sold USANA Health Sciences company stock in the last year include Daniel A Macuga, David Mulham Mulham, G Doug Iiekking, Gilbert A Fuller, Global Ltd Gull, James Bramble, Jim Brown, Kevin Guest, Myron W Wentz, Paul A Jones and Walter Noot. View Insider Buying and Selling for USANA Health Sciences.

USNA stock was purchased by a variety of institutional investors in the last quarter, including Matarin Capital Management LLC, Hood River Capital Management LLC, BlackRock Inc., Russell Investments Group Ltd., Millennium Management LLC, Fort L.P., Schwab Charles Investment Management Inc. and Mackay Shields LLC. View Insider Buying and Selling for USANA Health Sciences.

Shares of USNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of USNA stock can currently be purchased for approximately $118.25.

USANA Health Sciences has a market capitalization of $2.86 billion and generates $1.05 billion in revenue each year. The company earns $62.53 million in net income (profit) each year or $4.06 on an earnings per share basis. USANA Health Sciences employs 1,810 workers across the globe.

USANA Health Sciences' mailing address is 3838 West Parkway Blvd, Salt Lake City UT, 84120. The company can be reached via phone at 801-954-7100 or via email at 0.